Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (962) clinical trials

A research study is evaluating an investigational medication for mild Alzheimer’s Disease dementia. This research study may be an option for your loved one if: They are 55-85 years of age They have a diagnosis of mild Alzheimer’s Disease dementia All their medication is stable for at least 30 days ...

Phase N/A

The purpose of the study is to determine whether lowering systolic blood pressure and cholesterol, alone or in combination with aerobic exercise, can improve memory function of the brain in older adults at higher risk for developing dementia. This study will last 2 years. There are outpatient visits (2-5 hours ...

Phase N/A

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

Phase

This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Phase

SPRI is currently participating in a multi-center, 24-month clinical evaluation of an investigational drug for people suffering from mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD).

Phase N/A

SPRI Clinical Trials of Brooklyn, under the sponsorship of Suven Life Sciences, is currently participating in the clinical evaluation of the safety and effectiveness of an investigational drug in persons with moderate dementia due to Alzheimer’s disease.

Phase

Researchers are studying a drug called BAN2401 in people who have early Alzheimer's disease . People with Alzheimer's disease have a buildup of abnormal protein, known as amyloid, in their brains. BAN2401 may reduce the amount of this abnormal protein. The study drug will be given through injection into a ...

Phase

Eli Lilly and Company (Lilly) is developing LY3202626, a synthetic small molecule which is a potent inhibitor of β-site amyloid precursor protein (APP)-cleaving enzyme [BACE]1, for the treatment of Alzheimer’s disease (AD). It is hypothesized that inhibition of BACE1 may slow or inhibit the progression of AD. Study I7X-MC-LLCF (LLCF), ...

Phase